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the changes in business condition in Japan’s healthcare system. Methods: The 
financial statements of all 143 NHO hospitals from 2004 to 2013 were obtained to 
explore the changes in their financial conditions. We analysed them with total 
health expenditures and the revision rates of the medical fee schedule available 
from the government websites. Results: The medical fee schedule was reduced 
by 3.16% in 2006 and 0.82% in 2008, and then increased by 0.19% in 2010 and 0.004% 
in 2012. The change rate of the profit per bed in NHO hospitals was overall parallel 
to the change rate of total health expenditure except for 2010 when the change 
rates were increased in 6.9% and 3.9% respectively. The reason of the exception 
in 2010 can be associated with the transition to acute care in line with the gov-
ernment policy to promote functional differentiation of hospitals. NHO hospitals 
with more than 350 beds had continuously increased the change rate of profit 
per bed despite of the negative revisions to the medical fee schedule in 2006 and 
2008. ConClusions: Clear influence of the manipulation of the medical fee sched-
ule was observed over the profit per bed in NHO hospitals. The rate of increase in 
total health expenditure was fairly controlled by the government through the revi-
sion of the medical fee schedule.
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objeCtives: The aim of our study was to predict the future health insur-
ance expenditures according to the changes in the number of population in 
Hungary. Methods: Actual health insurance expenditure data for the base-case 
year (2013) were derived from the National Health Insurance Fund Administration 
(NHIFA) of Hungary and covered the following types of care: acute and chronic 
inpatient care, out-patient care, laboratory care, CT and MRI, drug, medical devices 
and home care. We analyzed health insurance expenditures according to age and 
gender. The prediction of future number of Hungarian population was calculated 
according to the population forecast of the Central Statistical Office of Hungary for 
2060. We applied 3 scenarios: basic, low and high number of population. Results: 
The actual health insurance expenditures of NHIFA was ö15.8 billion Hungarian 
Forint (HUF) in 2013 and the population of Hungary was 9910811 people. For the 
year 2030, health insurance expenditures were assessed 938.2 billion HUF while 
the population is predicted 9211522 people. For the year 2060, health insurance 
expenditures were assessed 908.5 billion HUF while the population is predicted 
7922289 people. Health insurance expenditures for population under 25 years was 
10.2 % of total expenditures, which decreased to 8.7 % in 2030 and 7.2 % in 2060. 
Health insurance expenditures for population over 65 years was 40.3 % of total 
expenditures, which increases to 47.0 % in 2030 and 58.9 % in 2060. ConClusions: 
Health insurance expenditures of Hungary will not increase significantly on actual 
level up to 2060. The reason behind this fact is the serious decline int he number of 
population. However, there will be a significant shift in the expenditures by decreas-
ing the proportion of population below 25 and increasing the proportion of people 
aged over 65 years.
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objeCtives: Italy has a tax-funded National Health System (NHS) that guar-
antees universal provision of comprehensive care. The central government 
provides policy and planning framework, defines the Essential Levels of Care 
and guarantees financial sustainability, while the regions are responsible 
for healthcare delivery and are liable for any budget deficit. Since 2005, cost-
containment and prescription appropriateness policies were developed in 
order to make regions more responsible on healthcare expenditure. The aim 
of this research was to provide an overview of national healthcare expendi-
ture trends before and after the implementation of such policies. Methods: 
Data published by the Minister for Economic and Financial Affairs were ana-
lysed to show different expenditure trends in different time periods: before 
2005 (period: 2002-2005) and after (2006-2013). Results: National healthcare 
expenditure from 2002-2013 increased by about € 30.28 billion (€ 78.97 in 2002 and 
€ 109.26 billion in 2013/year) with an average annual rate of +3.2%. Trends were 
different per period, with average annual rates of +5.4% in 2002-2005 and 
+1.3% in the period 2006-2013; +2.6% increase in the period 2006-2009 and 
-0.3% in 2010-2013. In the period 2006-2013, healthcare expenditures com-
ponents - such as healthcare professionals, general practitioners and hospi-
tal services - showed a lower average annual growth rate compared with the 
2002-2005 period. Territorial drug expenditures show a dramatic decrease 
compared to the previous period. ConClusions: Our analysis show that 
there is still room for better rationalise healthcare expenditure, however the 
greater empowerment of the regions and the policies implemented in recent 
years have improved the economic performance of the Italian healthcare 
expenditure.
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objeCtives: In Portugal, during the period 2002–2010, longevity (mean age at 
death) increased by 2.5 years. The aim of this study was to examine the effects of 
pharmaceutical innovation on the longevity from all diseases in Portugal (2002–
2010). Methods: Longitudinal disease-level data was analyzed to determine 
whether diseases for which there was greater pharmaceutical innovation - a larger 
nephrotic syndrome (1; 1.6%). ConClusions: Of the total of prescriptions, 76.1% 
were compliance with indications in national guidelines. However, unsubstantiated 
prescriptions represented a cost of around 22.0% of the total budget spent on the 
acquisition of albumin and that could have been applied in other unmet needs due 
to lack of financial resources.
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objeCtives: To assess the costs, benefits and savings of MobileCARE, an electronic 
health record (EHR) system smartphone application for clinical documentation 
developed by the United States Army and University of Miami, and implemented in a 
trauma intensive care unit (TICU). To evaluate provider perceptions of MobileCARE’s 
usability and impact on clinical workflow and productivity. Methods: A cost-
effectiveness and cost-utility analysis was conducted using hospital-level cost 
data and clinical outcomes data collected retrospectively at three time periods: 
pre-MobileCARE and two subsequent iterations of MobileCARE from 2010-2014. An 
analysis was performed of direct costs related to the mobile health intervention and 
benefits related to patient’s clinical outcomes. Qualitative interviews (n= 20) were 
conducted with providers working in the TICU and using MobileCARE. Ethnographic 
observation of clinical workflow and MobileCARE usage was conducted over the 
course of 12 days. Results: The total cost of MobileCARE was $2,655,639.67, con-
sisting of $1,943,399.47 towards platform development and a fixed, direct cost of 
implementation totaling $712,239.70. Transcription cost-savings per-provider were 
$79.25/month. Average length of stay decreased by 1.73 days, average mortality 
rate decreased by 2%, and QALDs increased by 1.8 QALD per patient over the study 
period. These clinical trends show directional improvement, although no significant 
differences were found. Overall, providers found MobileCARE acceptable, easy to 
use, positively impacted workflow, and increased their productivity. ConClusions: 
MobileCARE appears to be an affordable option for improving EHR usability, physi-
cian productivity, and clinical outcomes. The overall cost of developing MobileCARE 
is high, but consistent with similar technologies previously developed. The single-
time cost of implementation is justifiable given the ongoing cost-savings, time-
savings, indicated trends of clinical outcome benefits, and overall user acceptance 
of the system. MobileCARE is a viable option for TICU’s seeking low-cost and usable 
mobile documentation systems to enhance existing EHR system usability and effec-
tively reduce hospital transcription costs.
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objeCtives: An increase in prevalence of antimicrobial resistance among gram-
negative pathogens in complicated intra-abdominal infections (cIAI) has been noted 
recently (Sartelli et al 2013). A challenge in empiric treatment of cIAI is identifying 
initial appropriate antibiotic therapy (IAAT), which is associated with reduced length 
of stay and mortality compared with inappropriate therapy. Using local antibiogram 
data to select empiric therapy may increase the likelihood of IAAT. The objective of 
this research is to demonstrate how an economic model can assist medical decision-
making by identifying threshold differences in antibiotic resistance at which cef-
tolozane/tazobactam+metronidazole is cost-effective/cost-saving compared with 
piperacillin/tazobactam as IAAT. Methods: We used a decision analytic Monte 
Carlo simulation model (Kauf et al 2015) to compare cost and QALYs of persons 
infected with nosocomial gram-negative cIAI and treated empirically with either 
ceftolozane/tazobactam+metronidazole or piperacillin/tazobactam. We ran the 
model for baseline prevalence of resistance in the Program to Assess Ceftolozane/
Tazobactam Susceptibility (PACTS) in-vitro surveillance database. We limited thresh-
old analysis to three commonly isolated gram-negative pathogens: Escherichia coli, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa. We assumed resistance for 
both drugs to be similar and then increased resistance in the piperacillin/tazobactam 
arm for all three pathogens simultaneously. Threshold differences in resistance at 
which ceftolozane/tazobactam became cost-effective were estimated. Results: 
At baseline resistance levels from PACTS, ceftolozane/tazobactam+metronidazole 
was cost-saving compared with piperacillin/tazobactam. Ceftolozane/tazobactam 
was cost-effective (cost-saving) when resistance rates for the three bacteria in the 
piperacillin/tazobactam were > 2% (7%) relative to ceftolozane/tazobactam. When 
resistance rates for E. coli alone were changed, ceftolozane/tazobactam was cost-
effective (cost-saving) at differences > 3% (13%). Results were sensitive to gram-
positive/-negative pathogen prevalence, drug/hospitalization cost. ConClusions: 
Economic models can be used to identify IAAT based on in-vitro resistance data. 
Once threshold differences in antibiotic resistance that make a comparator drug 
cost-effective are established, local antibiograms can help identify optimal IAAT.
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objeCtives: Ministry of Health, Labour and Welfare of Japan revises medical fee 
schedule biennially. The revision is performed in line with the government’s budget 
policy at national level. This study explored the influence of the manipulation of the 
medical fee schedule on National Hospital Organization (NHO) hospitals to overview 
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were utilized to simulate a Cost-Effectiveness Acceptability Curve of each clinical 
area and type of intervention i.e. screening or vaccination program. Results: 
The cost-effectiveness function of prevention programs yield an ICER < € 30.000/
QALY in 80% of realizations. Vaccines are the most efficient interventions, since 
they exhibit an ICER lower than treatments of the same clinical in more than 90% 
of simulations ConClusions: Prevention programs typically require immedi-
ate investments yielding future health benefits. To acknowledge this peculiarity 
means to adopt not only a short (Vaccinations against influenza , chicken pox 
, measles), but also a medium (vaccination against zoster, genital warts , and 
tetanus) and long time horizon (screening of cancers and hepatitis) when assess-
ing the efficiency of healthcare programs. Failure to reach the threshold of 5 % 
of spending on prevention required by Italian national healthcare planning, is 
therefore to be understood as a form of rationing, rather than rationalization of 
healthcare resources.
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objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when 
wholesalers were also authorized, pharmaceuticals under this status could only 
be imported by the Turkish Pharmacists’ Association (TPA The aim of this study 
is to understand the trends in L subgroups (Antineoplastic and immunomodu-
lating agents) of ATC classification system unlicensed medicine consumption 
between 2011 and 2013 when the TPA was the only authorized supplier. Methods: 
Consumption data of L sub-group in the top 100 imported unlicensed medicines 
with the highest sales share in total expenses of imported off-label use was taken 
from the TMMDA computer database. L01, L02, L03 and L04 were taken as subgroups. 
Descriptive analysis was conducted. Results: The analysis showed that the L01 
had the highest percentage of active ingredients among L subgroups with 67% share 
in all L group medicines. The percentage of L01 rose from 67% to 76% between 2011 
and 2013. The consumption of L01 rose from 61 million TL to 230 million TL in the 
same period. L01 has the highest percentage of unit sales as well. ConClusions: 
The cost of imported medicines used in off-label use is increasing every year in 
Turkey. Some cost-containment measures (especially for L01-antineoplastic agents) 
should be taken to reduce the cost without risking patients’ access to innovative 
medicines.
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objeCtives: Medication errors are unintentional errors in how medicines are pre-
scribed, dispensed, administered, or monitored while controlled by a healthcare 
professional, patient, or consumer. Leendertse et al (2008) reported that 5.6% of 
acute hospital admissions are medication-related, of which 46.5% were poten-
tially preventable. This study estimated the costs related to medication errors 
that lead to avoidable hospitalizations in Belgium. Methods: Based on the inci-
dences from Leendertse et al (2008), the number of hospital admissions due to 
avoidable medication errors in Belgium was determined. The total avoidable costs 
attributable to medication errors was estimated, by multiplying the number of 
avoidable hospitalizations with the average cost of a hospital stay, calculated 
using the online official database of the Technical Cell (data from 2011). Costs 
were inflated to 2014. Results: The estimated average cost of a hospital stay in 
Belgium was € 4,886. Based on 2.6%, the incidence rate of total hospital admissions 
attributable to medication errors, 42,797 hospital admissions that could have been 
avoided due to medication errors were estimated. Avoiding these hospitaliza-
tions would produce potential savings of € 209Mn per year. ConClusions: This 
study shows that the economic and health burden of preventable medication 
errors is high. As such, a synergic approach is warranted nationally and across 
national borders. This should entail communication and involvement from all 
different stakeholders (medical doctors, pharmacists, hospitals, national and 
international pharmacovigilance organizations) in the provision and delivery 
of care.
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objeCtives: Prior to February 2013, price management within Astellas Pharma 
Europe Ltd. was done manually using an Excel database. The system was labour 
intensive, slow to update, and prone to error. We developed an innovative web-
based pricing information management system to address the shortcomings of the 
previous system. Methods: A secure web-based system for submitting, review-
ing and approving pricing requests was developed for use by 21 affiliates in 40 
countries in Europe, Middle East and Africa. The aims of the new system were 
to: (i) reduce time/effort to approve price change requests; (ii) reduce the risk of 
using incorrect/unapproved prices; (iii) improve the visibility of pricing data to 
affiliates; (iv) improve approval process compliance. The system was designed 
to: track all pricing applications and approval status; update approved pricing 
information automatically; provide fixed and customisable reports of pricing 
increase in the number of new chemical entities (NCEs) previously launched (1994-
2002) - had higher increase in mean age at death, controlling for the effects of 
macroeconomic trends and overall changes in the healthcare system. Results: 
The diseases for which more drugs were registered during the period 1994-2002 
had larger increases in mean age at death during 2002-2010. The increase in mean 
age at death for “high-innovation diseases” (mean number of NCE 1994-2002 = 
12.9) was 3.1 years, while 1.7 years for “low-innovation diseases” (mean number 
of NCE 1994-2002 = 3.9). Furthermore, our estimates indicate that about 1/3 of the 
total increase in longevity (i.e. 0.8 years) was due to NCE 1994-2002. Thus, phar-
maceutical innovation increased mean age at death by 1.2 months per year. There 
were 106,242 deaths in Portugal in 2010. Hence the number of life-years gained in 
2010 due to drugs registered during the period 1994-2002 was 84,994 (= 0.80 years * 
106,242 deaths). ConClusions: These findings demonstrate that pharmaceutical 
innovation brought significant health gains in Portugal in the past decade. Access to 
innovation is therefore crucial if society desires to mantain the positive momentum 
of longevity increase.
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objeCtives: Antibiotic use outside hospital in Belgium is known to be one of 
the highest in Europe. This has aside an impact on resistance also an important 
economic burden. The aim of this study was to evaluate the potential savings that 
could be realized in case prescription behavior in Belgium would be similar to the 
Netherlands, a country known for its strict antibiotic use. Methods: Current 
spending levels for antibiotics were determined in Belgium and the Netherlands. 
Volume and value sales were determined per country (average number of pills sold 
per capita) based on IMS Health Belgian National Retail Database available to IMS 
Health in both countries via the IMS MIDAS platform (2013 data). The potential 
country-level prescription cost in Belgium was estimated by multiplying aver-
age number of pills/person in the Netherlands, with the cost/pill in Belgium and 
extrapolating the result to the total population in Belgium, assuming that prescrib-
ing levels in Belgium were equal to those in the Netherlands and using Belgian 
prices. Also reasons for antibiotic use were checked in the IMS Longitudinal 
Patient Database. Results: In Belgium the number of pills per capita was sig-
nificantly higher compared to the Netherlands (12.66 vs. 5.93 pills/person). With 
a 30% smaller population than the Netherlands, spending in Belgium is 3 times 
higher. The estimated savings for the Belgian payer applying the usage (pill/per-
son) of the Netherlands and current cost/pill in Belgium were € 71.5 Mn. Reasons 
for antibiotics prescription in Belgium were mainly upper airway infections and 
bronchitis. ConClusions: By comparing Belgium’s prescription patterns to the 
Netherlands, we estimated important potential savings due to antibiotics mis-use/
over-use. The additional health and cost implications of antibiotics resistance 
were not taken into account. These savings could then be reinvested in covering 
innovative drugs.
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objeCtives: The aim of this study is to analyze the impact of multimorbidity on 
ambulatory pharmaceutical cost and hospital cost. We use Clinical Risk Groups 
(CRG) for determining the multimorbidity. CRG is a classification system for risk 
adjustment which assigns each individual to risk groups based on chronic condi-
tion. Methods: In a cross-sectional study we extracted the data of cost and co-
morbidity using CRGs from a data base of 156.811 people register with the health 
district of Denia, in eastern Spain, during 2013. Two OLS models were constructed for 
natural logarithm of the dependent variable of pharmaceutical and the other being 
hospital cost per patient respectively. Both models we take as independent variables 
the nine main health status of CRG. Results: The ambulatory pharmaceutical 
cost represents 27.00% of the total expenditure. The CRG with the highest related 
ambulatory costs was CRG 7 (Dominant chronic disease in 3 or more organ systems 
(38.77%)). The highest hospital costs were found to be in the groups of higher sever-
ity levels (8.Dominant and metastatic malignances and 9.Catastropihc conditions), 
being 80.86% and 85.23% respectively. The statistical analysis showed a higher level 
of significance in the ambulatory pharmaceutical cost model: R squared of 58.8% 
versus the 12.8% in the hospital model. ConClusions: There is wide variability 
in the percentage of outpatient expenditure between the different status levels of 
the CRG. The explanatory capacity of the CRG is much higher when it is outpatient 
cost because patients suffering with chronic conditions are regular users of the 
Primary Care than of Hospital Care.
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objeCtives: To review evidence on cost-effectiveness of screening and vaccina-
tion programs currently funded in Italy, in order to develop a tool to appraise the 
efficiency of healthcare expenditure on prevention. Methods: Cost-utility studies 
carried out in Italy between 1995 and 2014 where gathered though PubMed search 
engine. The following inclusion criteria were applied to the records retrieved: (i) 
Cost-Utility analysis; (ii) Italian setting; (iii) National Health Service Perspective; 
(iv) lifetime horizon; (v) intervention belonging to one of these clinical area: viral 
hepatitis, cancers, metabolic and cardiovascular diseases; infectious or respiratory 
disease. Prevention programs have been ordered in league tables. Mean and stand-
ard deviation of incremental values and ICERs reported in the selected studies 
